Review: Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies
- 5 October 2009
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 3 (1), 55-66
- https://doi.org/10.1177/1756283x09346669
Abstract
The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with new hope. The treatment of HCC is multidisciplinary, requiring surgeons, hepatologists, interventional radiologists and oncologists. Thus, there is enormous potential to combine various treatment modalities to improve survival for patients. This review will describe what is currently known about the molecular pathogenesis of HCC, explore current and future treatments based on these pathways, and describe how these new therapies fit into existing approaches to HCC treatment.Keywords
This publication has 82 references indexed in Scilit:
- α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular CarcinomaGastroenterology, 2009
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Molecular targeted therapies in hepatocellular carcinomaHepatology, 2008
- Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be ExpandedAnnals of Surgery, 2007
- Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosisHepatology, 2005
- Randomized controlled trial of screening for hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- The Hallmarks of CancerCell, 2000